Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R7-CLIC1pep-linked E3 ligase peptide is a peptide-based proteolysis-targeting chimera (ProTAC) designed to target and degrade chloride intracellular channel protein 1 (CLIC1). Developed by researchers at Kyungpook National University, the molecule consists of three functional components: a hepta-arginine (R7) cell-penetrating peptide to facilitate intracellular delivery, a CLIC1-binding peptide (CLIC1pep) identified through phage display, and an E3 ligase-recruiting peptide. CLIC1 is a metamorphic protein upregulated in various cancers, including hepatocellular carcinoma and lung cancer, where it promotes angiogenesis, migration, and metastasis. By recruiting an E3 ligase to CLIC1, this therapeutic candidate induces the ubiquitination and subsequent proteasomal degradation of the target protein, thereby inhibiting tumor cell migration and invasion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on R7-CLIC1pep-linked E3 ligase peptide.